Key Highlights
- NextCure (NXTC) shares skyrocketed more than 300% on Tuesday following the announcement of an all-stock merger agreement with privately-owned Avere Therapeutics
- A simultaneous $320 million private placement financing round is being spearheaded by Fairmount and Hansoh Pharmaceutical
- Post-merger, the unified entity will list on Nasdaq trading under AVRX, with deal completion anticipated in late 2026
- Current NextCure shareholders will control roughly 1.21% of the newly formed organization
- The transaction is focused around AVR-001, a weekly oral IL-23 receptor antagonist being developed for psoriasis and ulcerative colitis treatment
NextCure (NXTC) shares witnessed an explosive surge exceeding 300% on Tuesday following the clinical-stage biotechnology company’s revelation of a merger agreement with private entity Avere Therapeutics, supported by $320 million in new capital.
Notwithstanding the dramatic one-day rally, shares continue trading approximately 84% lower year-to-date, carrying a market capitalization of merely $7.87 million prior to the merger disclosure.
The all-equity merger will result in the consolidated enterprise operating as Avere Therapeutics and listing on Nasdaq with the ticker AVRX. Transaction completion is projected for the latter half of 2026.
The $320 million private financing encompasses $251 million in convertible notes that will transform into common equity upon deal closure. Fairmount and Hansoh Pharmaceutical spearheaded the funding round, joined by Venrock Healthcare Capital Partners, General Atlantic, Janus Henderson Investors, and Wellington Management.
At the heart of this merger sits Avere’s flagship candidate, AVR-001 — an orally administered, once-weekly IL-23 receptor antagonist in development for inflammatory diseases such as psoriasis and ulcerative colitis.
Avere recently secured licensing rights to AVR-001 from Hansoh, obtaining commercial rights for territories outside Greater China. Hansoh collected $120 million upfront and stands to receive as much as $2.18 billion through development and commercial milestone achievements, along with ongoing royalty payments.
The newly raised capital will support a Phase 2b psoriasis clinical trial, initiate a Phase 3 psoriasis program, and fund a Phase 2b ulcerative colitis investigation. An IND application for AVR-001 in the United States has already been activated, with Phase 2b commencement planned for early 2027 and initial data anticipated during the first half of 2028.
Leadership Structure
Dr. Andrew Cheng, currently Avere’s CEO, will assume leadership of the merged entity as Chief Executive Officer, President, and Chairman of the Board. Kitty Yale will serve as Chief Development Officer, William White will take the CFO position, and Brett Pletcher will function as General Counsel.
Michael Richman, NextCure’s present CEO, characterized the transaction as “a compelling opportunity” for existing shareholders to gain exposure to AVR-001’s clinical advancement.
Shareholder Considerations
Existing NextCure shareholders will retain approximately 1.21% ownership in the combined company — a proportion that mirrors NextCure’s current valuation compared to Avere.
Additionally, they will receive contingent value rights granting them 90% of net proceeds generated from any potential monetization of NextCure’s current pipeline programs during a two-year period following transaction completion.
Tuesday’s trading volume exceeded 44 million shares. This represents a stark contrast to the stock’s three-month average daily volume of approximately 37,000 shares.
Analyst sentiment on NXTC stands at Moderate Buy, supported by two Buy recommendations issued over the past three months, with a consensus price target of $20 per share.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
